NewsBenzingaMarker Therapeutics Secures $2.6M From FDA Through Its Orphan Products Clinical Trials Grants Program To Support Phase 1 Clinical Study Evaluating Lead Investigational MAR-T Cell Therapy, MT-601, In Pancreatic Cancer Marker Therapeutics Secures $2.6M From FDA Through Its Orphan Products Clinical Trials Grants Program To Support Phase 1 Clinical Study Evaluating Lead Investigational MAR-T Cell Therapy, MT-601, In Pancreatic Cancer Benzinga 2026.10.19 11:04 (GMT+0) Open on Benzinga Other news MIIT and Seven Other Departments: Accelerate AI Implementation Across Product R&D, Design Simulation, Pilot Verification, and Production Operations Kanye West-linked address goes long ETH via Aave looping, withdrawing a total of 12,549.9 ETH Report: Microsoft's headcount declines for first time in a decade, down about 5,000 in FY2026 GMX proposal plans to use remaining Solana-side revenue for buybacks and introduce a 180-day unstaking waiting period Broadcom's M&A Strategy Is A Value Play (NASDAQ:AVGO) Crown Castle Inc. (CCI) Q3 2026 Earnings Call Transcript
MIIT and Seven Other Departments: Accelerate AI Implementation Across Product R&D, Design Simulation, Pilot Verification, and Production Operations
GMX proposal plans to use remaining Solana-side revenue for buybacks and introduce a 180-day unstaking waiting period
